

Financial news for PTLA dated on 2020-05-22: Portola Pharmaceuticals Option Alert: Jan 15 \$17.5 Puts Sweep (8) near the Bid: 504 @ \$0.25 vs 7198 OI; Ref=\$17.835

Financial news for PTLA dated on 2020-05-12: UPDATE: Elliott's Letter To Alexion Board

Financial news for PTLA dated on 2020-05-12: Elliott Advisors Says Portola's 'Lack Of Obvious Strategic Fit' With Alexion Is What Drove 'Bulk Of The Market's Negative Reaction, In Our View'

Financial news for PTLA dated on 2020-05-12: Portola Pharma Shares Volatile, Very Slightly Lower, Following Letter From Elliott Advisors To Alexion Criticizing Deal With Co.

Financial news for PTLA dated on 2020-05-11: Portola Pharma Cut FY20 Opex Guidance By ~\$50M

Financial news for PTLA dated on 2020-05-11: Portola Pharmaceuticals Q1 EPS \$(0.880) Misses \$(0.800) Estimate, Sales \$26.389M Miss \$33.860M Estimate

Financial news for PTLA dated on 2020-05-08: Morgan Stanley Maintains Equal-Weight on Portola Pharmaceuticals, Raises Price Target to \$18

Financial news for PTLA dated on 2020-05-06: 70 Biggest Movers From Yesterday

Financial news for PTLA dated on 2020-05-05: Mid-Afternoon Market Update: NASDAQ Surges More Than 2%; Itron Shares Slide

Financial news for PTLA dated on 2020-05-05: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PTLA dated on 2020-05-05: Mid-Day Market Update: Crude Oil Jumps 19%; Fulgent Genetics Shares Plunge Following Q1 Earnings

Financial news for PTLA dated on 2020-05-05: Portola Pharmaceuticals: P/E Ratio Insights

Financial news for PTLA dated on 2020-05-05: Mid-Morning Market Update: Markets Open Higher; Sysco Misses Q3 Views

Financial news for PTLA dated on 2020-05-05: What You Should Know About Alexion's \$1.4B Proposed Buyout Of Portola Pharma

Financial news for PTLA dated on 2020-05-05: Portola Pharmaceuticals shares are trading higher after the company announced it will be acquired by Alexion for \$18 per share in cash.

Financial news for PTLA dated on 2020-05-05: Alexion Reports Purchase Of Portola Pharma For \$18/Share In Cash

Financial news for PTLA dated on 2020-04-23: Portola Pharmaceuticals shares are trading higher after RBC analysts initiated coverage on the company with an Outperform rating and \$20 price target.

Financial news for PTLA dated on 2020-04-23: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for PTLA dated on 2020-04-23: RBC Capital Initiates Coverage On Portola Pharmaceuticals with Outperform Rating, Announces Price Target to \$20

Financial news for PTLA dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for PTLA dated on 2020-04-01: Portola Pharmaceuticals Option Alert: Apr 17 \$7.5 Calls Sweep (3) near the Ask: 813 @ \$0.3 vs 7860 OI; Earnings 5/6 Before Open [est] Ref=\$6.48

Financial news for PTLA dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for PTLA dated on 2020-03-18: Portola Pharmaceuticals announces Proactive Steps Including Suspending Face-To-Face Field Activity and Instituted A Mandatory Work From Home Policy For All Employees

Financial news for PTLA dated on 2020-03-18: The Daily Biotech Pulse: AbbVie,

Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for PTLA dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for PTLA dated on 2020-03-16: Portola Pharmaceuticals shares are trading lower despite the company announcing the results of its Andexxa. NOTE: The overall market is trading lower amid continued coronavirus fears hampering the global economy.

Financial news for PTLA dated on 2020-03-16: Portola Pharmaceuticals Announces Results Demonstrating Andexxa Was 'Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds'

Financial news for PTLA dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for PTLA dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for PTLA dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for PTLA dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for PTLA dated on 2020-03-10: Stocks That Hit 52-Week Lows On Tuesday

Financial news for PTLA dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for PTLA dated on 2020-03-05: Portola Pharma Highlights Presentation Of New Data Showing Andexxa To Treat Patients With ICH At Emergencies In Medicine Meeting

Financial news for PTLA dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for PTLA dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for PTLA dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for PTLA dated on 2020-02-28: 140 Biggest Movers From Yesterday

Financial news for PTLA dated on 2020-02-27: 100 Stocks Moving In Thursday's Mid-Day Session

Financial news for PTLA dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for PTLA dated on 2020-02-27: Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.

Financial news for PTLA dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for PTLA dated on 2020-02-26: Stocks That Hit 52-Week Lows On Wednesday

Financial news for PTLA dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for PTLA dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for PTLA dated on 2020-01-31: The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO

Financial news for PTLA dated on 2020-01-30: Stocks That Hit 52-Week Lows On Thursday

Financial news for PTLA dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for PTLA dated on 2020-01-27: Stocks That Hit 52-Week Lows On Monday

Financial news for PTLA dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for PTLA dated on 2020-01-13: 55 Biggest Movers From Friday

Financial news for PTLA dated on 2020-01-10: Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet

Financial news for PTLA dated on 2020-01-10: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for PTLA dated on 2020-01-10: Stocks That Hit 52-Week Lows On Friday

Financial news for PTLA dated on 2020-01-10: Benzinga's Top Upgrades, Downgrades For January 10, 2020

Financial news for PTLA dated on 2020-01-10: Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump

Financial news for PTLA dated on 2020-01-10: Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For \$18.75/Share

Financial news for PTLA dated on 2020-01-10: 10 Biggest Price Target Changes For Friday

Financial news for PTLA dated on 2020-01-10: Portola Pharmaceuticals shares are trading lower after the company reported preliminary FY19 Andexxa global net revenues of \$111 million.

Financial news for PTLA dated on 2020-01-10: 21 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for PTLA dated on 2020-01-10: Oppenheimer Downgrades Portola Pharmaceuticals to Perform, Lowers Price Target to \$17

Financial news for PTLA dated on 2020-01-10: 33 Stocks Moving in Friday's Pre-Market Session

Financial news for PTLA dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for PTLA dated on 2020-01-09: Portola Pharmaceuticals shares are trading lower after the company reported preliminary FY19 Andexxa global net revenues of \$111 million.

Financial news for PTLA dated on 2020-01-09: Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately \$111 Million

Financial news for PTLA dated on 2019-12-09: Portola Pharma Highlights Presentation Of New Interim Data On Oral Cerdulatinib At ASH

Financial news for PTLA dated on 2019-12-08: Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

Financial news for PTLA dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for PTLA dated on 2019-11-08: Goldman Sachs Initiates Coverage On Portola Pharmaceuticals with Neutral Rating

Financial news for PTLA dated on 2019-11-06: Portola Pharmaceuticals shares are trading lower despite the company reporting better-than-expected Q3 EPS and sales results.

Financial news for PTLA dated on 2019-11-05: Portola Pharmaceuticals Q3 EPS \$(0.68) Beats \$(0.82) Estimate, Sales \$36.8M Beat \$34.63M Estimate

Financial news for PTLA dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for PTLA dated on 2019-10-28: Portola Pharmaceuticals To Present New Analysis From ANNEXA-4 Study Of Its Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Acute Gastrointestinal Bleeding At American College Of Gastroenterology Oct. 29

Financial news for PTLA dated on 2019-10-09: Citigroup Maintains Buy on Portola

Pharmaceuticals, Lowers Price Target to \$44

Financial news for PTLA dated on 2019-08-14: 32 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for PTLA dated on 2019-08-13: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PTLA dated on 2019-08-13: 31 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PTLA dated on 2019-08-13: A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Consumer Price Index

Financial news for PTLA dated on 2019-08-13: The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

Financial news for PTLA dated on 2019-08-13: 7 Stocks To Watch For August 13, 2019

Financial news for PTLA dated on 2019-08-12: 8 Stocks Moving In Monday's After-Hours Session

Financial news for PTLA dated on 2019-08-12: Portola Pharma shares are trading lower after the company reported a \$200 million common stock offering.

Financial news for PTLA dated on 2019-08-12: Portola Pharma Reports \$200M Common Stock Offering

Financial news for PTLA dated on 2019-08-09: 110 Biggest Movers From Yesterday

Financial news for PTLA dated on 2019-08-08: 90 Stocks Moving In Thursday's Mid-Day Session

Financial news for PTLA dated on 2019-08-08: Portola Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for PTLA dated on 2019-08-08: 52 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTLA dated on 2019-08-07: Portola Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for PTLA dated on 2019-08-07: Portola Pharmaceuticals Q2 EPS \$(0.97) Beats \$(1.03) Estimate, Sales \$28.4M Beat \$25.54M Estimate

Financial news for PTLA dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for PTLA dated on 2019-08-06: Portola Announces First European Orders For Ondexxya (Andexanet Alfa)

Financial news for PTLA dated on 2019-08-05: Credit Suisse Assumes Portola Pharmaceuticals at Neutral, Announces \$35 Price Target

Financial news for PTLA dated on 2019-08-05: Portola Pharma Announces that the US Centers for Medicare and Medicaid Services Has Increased the Maximum Reimbursement Amount for the New Technology Add-on Payment Granted in October 2018 to Andexxa

Financial news for PTLA dated on 2019-07-10: Credit Suisse Assumes Portola Pharmaceuticals at Neutral

Financial news for PTLA dated on 2019-07-08: Portola Pharmaceuticals Highlights Presentation Of New In Vitro Data Demonstrating That Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect On Inhibition Of Thrombin Generation By Factor Xa Inhibitors

Financial news for PTLA dated on 2019-06-19: Portola Pharma Highlights New Interim Data On Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

Financial news for PTLA dated on 2019-05-31: Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.

Financial news for PTLA dated on 2019-05-22: Portola Pharmaceuticals Announces New Analysis From The Annexa-4 Study Of Its Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Spontaneous Intracranial Hemorrhage; Excellent Or Good Hemostasis

Achieved In 79% Of Evaluable Patients

Financial news for PTLA dated on 2019-05-20: 31 Stocks Moving In Monday's Pre-Market Session

Financial news for PTLA dated on 2019-05-08: Portola Pharmaceuticals Q1 EPS \$(1.02) Up From \$(1.28) YoY, Sales \$22.169M Up From \$6.644M YoY

Financial news for PTLA dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for PTLA dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for PTLA dated on 2019-04-26: Portola Pharmaceuticals Announces That The European Commission Has Granted Conditional Marketing Authorization For Ondexxya; Initial Launch In Select Countries To Begin 2H 201

Financial news for PTLA dated on 2019-03-21: The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

Financial news for PTLA dated on 2019-03-20: Portola Pharma Reports Co-Founder Charles Homey Retires; Board Has Engaged Search For New Independent Director

Financial news for PTLA dated on 2019-03-04: 81 Biggest Movers From Friday

Financial news for PTLA dated on 2019-03-01: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for PTLA dated on 2019-03-01: Portola Pharma shares are trading higher after the company announced its Ondexxya recieved a positive opinion from Europe's Committee for Medicinal Products.

Financial news for PTLA dated on 2019-03-01: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for PTLA dated on 2019-03-01: Portola Pharma Reports CHMP Positive Opinion On Ondexxya

Financial news for PTLA dated on 2019-03-01: Earnings Scheduled For March 1, 2019

Financial news for PTLA dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for PTLA dated on 2019-02-07: Portola Pharmaceuticals Announces Full Results From ANNEXA-4 Study Of Factor Xa Inhibitor Reversal Agent Andexxa In Patients With Life-Threatening Bleeding; Achieved 'Excellent Or Good' Homeostasis In 82% Of Patients

Financial news for PTLA dated on 2019-01-02: 50 Biggest Movers From Monday

Financial news for PTLA dated on 2018-12-31: Portola Pharma Shares Resume, Up 7% For Session

Financial news for PTLA dated on 2018-12-31: Portola Pharma Shares To Resume Trade At 3:40 p.m. EST

Financial news for PTLA dated on 2018-12-31: Portola Sees Full Commercial Launch Of Andexxa Gen 2 Manufacturing Process Beginning Jan. 2019

Financial news for PTLA dated on 2018-12-31: FDA Approves Portola Pharma's Prior Approval Supplement For Andexxa Gen-2 Manufacturing Process

Financial news for PTLA dated on 2018-12-31: Portola Pharma Shares Halted Ahead Of PDUFA Announcement For Gen-2 Andexxa

Financial news for PTLA dated on 2018-12-31: Portola Pharma Shares Halted News Pending

Financial news for PTLA dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for PTLA dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for PTLA dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for PTLA dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks

Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for PTLA dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for PTLA dated on 2018-12-13: 52 Biggest Movers From Yesterday

Financial news for PTLA dated on 2018-12-11: Portola Pharmaceuticals shares are trading lower after the CHMP, a committee of the European Medicines Agency, announced it has extended the review period for the company's marketing authorization application for Ondexxya and delayed the Oral Explanation.

Financial news for PTLA dated on 2018-12-11: European Medicines Agency Committee Extends Review Period For Portola Pharmaceuticals' Ondexxya

Financial news for PTLA dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for PTLA dated on 2018-12-04: Portola Pharmaceuticals Presents Updated Interim Results from Ongoing Phase 2a Study of Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies at ASH 2018

Financial news for PTLA dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for PTLA dated on 2018-11-30: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for PTLA dated on 2018-11-09: 80 Biggest Movers From Yesterday

Financial news for PTLA dated on 2018-11-08: 65 Stocks Moving In Thursday's Mid-Day Session

Financial news for PTLA dated on 2018-11-08: Mid-Day Market Update: Dow Turns Higher; Koppers Holdings Shares Drop Following Weak Q3 Results

Financial news for PTLA dated on 2018-11-08: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 7, 2018

Financial news for PTLA dated on 2018-11-08: Mid-Morning Market Update: Markets Open Lower; Cardinal Health Tops Q1 Views

Financial news for PTLA dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for PTLA dated on 2018-11-08: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTLA dated on 2018-11-07: Portola Pharma Q3 EPS \$(1.08) Beats \$(1.62) Estimate, Sales \$14.177M Beat \$7.1M Estimate

Financial news for PTLA dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for PTLA dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for PTLA dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for PTLA dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for PTLA dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for PTLA dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for PTLA dated on 2018-10-18: Portola Pharmaceuticals 13G Shows Deerfield Management Raised Stake In Co. From ~1.45M Shares To ~3.55M Shares

Financial news for PTLA dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for PTLA dated on 2018-10-03: Stocks Which Set New 52-Week Low Yesterday, October 2nd

Financial news for PTLA dated on 2018-09-25: Portola Pharmaceuticals Receives FDA Orphan Drug Designation For Cerdulatinib, An Oral Syk/JAK Inhibitor For Treatment Of Peripheral T-Cell Lymphoma

Financial news for PTLA dated on 2018-09-20: Portola Pharmaceuticals Names Scott Garland President And CEO

Financial news for PTLA dated on 2018-09-12: FDA Late Tuesday Announced December 31 PDUFA Date For Portola Pharmaceuticals' Prior Approval Supplement For Generation 2 Andexxa Manufacturing Process

Financial news for PTLA dated on 2018-09-12: The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

Financial news for PTLA dated on 2018-09-11: FDA Assigns PDUFA Date December 31, 2018 to Portola Pharmaceuticals' Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process

Financial news for PTLA dated on 2018-08-31: Portola Pharmaceuticals Submits Prior Approval Supplement To FDA For Large-Scale Generation 2 Andexxa Manufacturing Process

Financial news for PTLA dated on 2018-08-27: Sympathy Move: Portola Upgraded After Competitor Reports Sour Data

Financial news for PTLA dated on 2018-08-27: 6 Biggest Price Target Changes For Monday

Financial news for PTLA dated on 2018-08-27: Benzinga's Top Upgrades, Downgrades For August 27, 2018

Financial news for PTLA dated on 2018-08-27: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for PTLA dated on 2018-08-27: Credit Suisse Upgrades Portola Pharmaceuticals to Neutral, Raises Price Target to \$34

Financial news for PTLA dated on 2018-08-25: Insider Buys Of The Week: Andeavor, Corcept, Portola

Financial news for PTLA dated on 2018-08-21: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PTLA dated on 2018-08-17: Stocks Which Set New 52-Week Low Yesterday, August 16th

Financial news for PTLA dated on 2018-08-16: Stocks Which Set New 52-Week Low Yesterday, August 15th

Financial news for PTLA dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for PTLA dated on 2018-08-15: Stocks Which Set New 52-Week Low Yesterday, August 14th

Financial news for PTLA dated on 2018-08-14: The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

Financial news for PTLA dated on 2018-08-10: 10 Biggest Price Target Changes For Friday

Financial news for PTLA dated on 2018-08-10: Benzinga's Top Upgrades, Downgrades For August 10, 2018

Financial news for PTLA dated on 2018-08-10: Credit Suisse Downgrades Portola Pharmaceuticals to Underperform, Lowers Price Target to \$28

Financial news for PTLA dated on 2018-08-10: 77 Biggest Movers From Yesterday

Financial news for PTLA dated on 2018-08-09: 68 Stocks Moving In Thursday's Mid-Day Session

Financial news for PTLA dated on 2018-08-09: Portola Pharmaceuticals shares are trading 17% lower to \$31.31 after the company reported weak quarterly financial results.

Financial news for PTLA dated on 2018-08-09: The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Financial news for PTLA dated on 2018-08-09: Portola Pharmaceuticals Q2 EPS \$(1.61) Misses \$(1.49) Estimate, Sales \$4.011M Miss \$6.35M Estimate

Financial news for PTLA dated on 2018-08-08: Portola Pharma's Q2 Earnings Outlook

Financial news for PTLA dated on 2018-07-27: UPDATE: Portola Pharma Interim Co-Pres Said, 'will maintain focus on the U.S. commercial launch as we continue to work toward our goal of expanding patient access to betrixaban around the world'

Financial news for PTLA dated on 2018-07-27: Portola Pharma Reports CHMP Maintains Negative Opinion On Betrixaban Following Appeal

Financial news for PTLA dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for PTLA dated on 2018-06-04: Portola Pharma Reports CEO Bill Lis To Retire; Board Has Begun Active Search For Replacement

Financial news for PTLA dated on 2018-06-04: Portola Pharmaceuticals Announces Interim Phase 2a Results For Oral SYK/JAK Inhibitor Cerdulatinib, Shows Efficacy In Patients and Demonstrates 'Broad Clinical Activity'

Financial news for PTLA dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for PTLA dated on 2018-05-24: Portola Pharmaceuticals Receives \$100M Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa

Financial news for PTLA dated on 2018-05-14: Jim Cramer Shares His Thoughts On Xerox, Booking Holdings And More

Financial news for PTLA dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for PTLA dated on 2018-05-09: Portola Pharmaceuticals Q1 EPS \$(1.28) Beats \$(1.52) Estimate, Sales \$6.644M Beat \$4.03M Estimate

Financial news for PTLA dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for PTLA dated on 2018-05-07: 43 Biggest Movers From Friday

Financial news for PTLA dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for PTLA dated on 2018-05-04: Mid-Afternoon Market Update: Dow Surges Around 400 Points; Portola Pharmaceuticals Shares Spike Higher

Financial news for PTLA dated on 2018-05-04: Portola Pharma Rips 20% Higher After FDA Approves Andexxa Antidote

Financial news for PTLA dated on 2018-05-04: 38 Stocks Moving In Friday's Mid-Day Session

Financial news for PTLA dated on 2018-05-04: Mid-Day Market Update: Crude Oil Up 2%; Fluor Shares Plummet

Financial news for PTLA dated on 2018-05-04: Portola Pharmaceuticals Shares Up 21.2% On FDA Approval of Andexxa

Financial news for PTLA dated on 2018-05-04: Mid-Morning Market Update: Markets Open Higher; Alibaba Tops Q4 Estimates

Financial news for PTLA dated on 2018-05-04: Benzinga Pro's 5 Stocks To Watch Today

Financial news for PTLA dated on 2018-05-04: Benzinga Pro's Most-Searched Tickers For Morning Of Fri., May 4, 2018

Financial news for PTLA dated on 2018-05-04: Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

Financial news for PTLA dated on 2018-05-04: 33 Stocks Moving In Friday's Pre-Market Session

Financial news for PTLA dated on 2018-05-04: UPDATE: Portola Pharma Shares Now Up 25.5%

Financial news for PTLA dated on 2018-05-04: Portola Pharma Shares Resume Trade, Now Indicated Up 3.3%

Financial news for PTLA dated on 2018-05-04: Portola Pharma Shares To Resume Trade At 7:15 a.m. EDT

Financial news for PTLA dated on 2018-05-04: Portola Pharma Shares Were Halted Ahead Of News FDA Approved Andexxa For Reversal Of Factor Xa Inhibitors

Financial news for PTLA dated on 2018-05-04: FDA Approves Portola Pharmaceuticals' Andexxa, Antidote for Reversal of Factor Xa Inhibitors

Financial news for PTLA dated on 2018-05-01: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Financial news for PTLA dated on 2018-04-30: Portola Pharm Option Alert: May 18 \$55 Calls Sweep (2) at the Bid: 879 @ \$0.7 vs 17326 OI; Earnings 5/7 After Close [est] Ref=\$36.765

Financial news for PTLA dated on 2018-04-30: The Week Ahead: Tesla And Apple Earnings, Dropbox Quiet Period Expires, Fed Rate Decision And More

Financial news for PTLA dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for PTLA dated on 2018-04-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for PTLA dated on 2018-03-23: Portola Pharma Reports CHMP Issued Negative Opinion For Betrixaban For Prevention Of VTE In Adults For Acute Medical Illness; Co. To Appeal Opinion, Seek Re-Examination

Financial news for PTLA dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for PTLA dated on 2018-03-02: 45 Biggest Movers From Yesterday

Financial news for PTLA dated on 2018-03-01: Mid-Afternoon Market Update: Dow Falls Over 300 Points; AxoGen Shares Spike Higher

Financial news for PTLA dated on 2018-03-01: Portola Pharmaceuticals Shares Down 25% As News Of Potential Delay Of U.S. Approval Of AndexXa Overshadows Q4 Earnings Beat

Financial news for PTLA dated on 2018-03-01: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for PTLA dated on 2018-03-01: Mid-Day Market Update: U.S. Stocks Turn Lower; Novavax Shares Gain On Positive Data

Financial news for PTLA dated on 2018-03-01: FDA Risk For Portola Pharma's Thrombosis Treatment Sends Morgan Stanley To Sideline

Financial news for PTLA dated on 2018-03-01: Mid-Morning Market Update: Markets Gain; Best Buy Beats Q4 Estimates

Financial news for PTLA dated on 2018-03-01: Benzinga's Top Upgrades, Downgrades For March 1, 2018

Financial news for PTLA dated on 2018-03-01: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTLA dated on 2018-03-01: Morgan Stanley Downgrades Portola Pharmaceuticals to Equal-Weight

Financial news for PTLA dated on 2018-02-28: Portola Pharma Reports Q4 EPS \$(1.41) vs \$(1.46) Est., Collaboration, License Sales \$9.8M vs \$6.2M Est.

Financial news for PTLA dated on 2018-02-28: Portola Pharmaceuticals Q4 Earnings Preview

Financial news for PTLA dated on 2018-02-22: Morgan Stanley Maintains Overweight on Portola Pharmaceuticals, Lowers price target to \$65.00

Financial news for PTLA dated on 2018-02-21: Credit Suisse Maintains Outperform on Portola Pharmaceuticals, Lowers price target to \$53.00

Financial news for PTLA dated on 2018-02-20: Portola Pharmaceuticals Announces CHMP Of EMA Has Communicated A Positive Trend Vote On The MAA For andexanet alfa

Financial news for PTLA dated on 2018-02-19: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for PTLA dated on 2018-01-23: Portola Pharmaceuticals Late Monday Announced Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18

Financial news for PTLA dated on 2018-01-23: Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18

Financial news for PTLA dated on 2018-01-08: How To Trade The JPMorgan Healthcare Conference

Financial news for PTLA dated on 2018-01-04: Portola Pharma Option Alert: Jan 19 \$50 Calls Sweep (2) at the Ask: 1000 @ \$2.0 vs 672 OI; Ref=\$49.94

Financial news for PTLA dated on 2017-12-27: 32 Biggest Movers From Yesterday

Financial news for PTLA dated on 2017-12-26: Mid-Afternoon Market Update: Crude Oil Up 2.5%; Aptose Biosciences Shares Spike Higher

Financial news for PTLA dated on 2017-12-26: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PTLA dated on 2017-12-26: Portola Pharma Shares Under Pressure After FDA Extension

Financial news for PTLA dated on 2017-12-22: Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa

Financial news for PTLA dated on 2017-12-19: Oppenheimer Serves Up 29 Top Stock Ideas For January

Financial news for PTLA dated on 2017-12-19: UPDATE: Portola Shares Up 3.7% For Session

Financial news for PTLA dated on 2017-12-19: Portola Pharma Shares At Session Highs, Spike Over \$49 Level Amid News FDA Approved Co.'s Prior Approval Supplement for Commercial Launch Of Bevyxxa

Financial news for PTLA dated on 2017-12-13: Portola Pharma Shares Not Reacting Following Oppenheimer Mid-Day Commentary Related To CHMP's Request For Added Info On Betrixaban MAA, Highlights Issues 'pertain strictly to betrixaban clinical data and not manufacturing'

Financial news for PTLA dated on 2017-12-12: Portola Pharma Says the European Medicines Agency Has Requested Additional Information Related to the Marketing Authorization Application for Betrixaban

Financial news for PTLA dated on 2017-12-01: Goldman Sachs Initiates Coverage On Portola Pharmaceuticals with Buy Rating, Announces \$75.00 Price Target

Financial news for PTLA dated on 2017-11-21: Portola Pharma Offers Update On Bevyxxa Launch: FDA Has Extended Review Period To Allow Agency Time To Review The Entire Submission

Financial news for PTLA dated on 2017-11-06: Portola Pharma Reports Q3 EPS \$(1.41) vs \$(1.46) Est., Collaboration, License Sales \$3.8M vs \$9.3M In Same Qtr. Last Year

Financial news for PTLA dated on 2017-11-06: Portola Pharmaceuticals Names Dr. John Lawrence Chief Medical Officer

Financial news for PTLA dated on 2017-09-27: Jim Cramer Advises His Viewers On Southwest Airlines And General Electric

Financial news for PTLA dated on 2017-09-19: 15 Biggest Mid-Day Losers For Tuesday

Financial news for PTLA dated on 2017-09-19: Portola Pharma Shares Tick ~\$0.35 Higher Over Last Few Mins As Traders Circulate Word Of Citi Defense On Name

Financial news for PTLA dated on 2017-09-19: Stat's Adam Feuerstein Tweets: \$PTLA \$350M financing done by MS, Citi, GS -- none of which bothered to ask about or look up new VTE clinical guidelines? Sloppy!

Financial news for PTLA dated on 2017-09-19: Stat's Adam Feuerstein Tweets: \$PTLA -11% today in part bc of my article but also investor anger. Company raised a lot of money w/o disclosing existence new guidelines.

Financial news for PTLA dated on 2017-09-19: Stat News Tweets: Commercial launch of Portola's new blood thinner could be threatened by new clinical guidelines

Financial news for PTLA dated on 2017-09-19: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PTLA dated on 2017-09-13: Portola Prices 6.35M Share Offering @\$55.00/Share

Financial news for PTLA dated on 2017-09-11: Portola Pharma Announces \$300M Offering Common Stock

Financial news for PTLA dated on 2017-08-25: Lightning Round: Jim Cramer Shares His Thoughts On Kite Pharma, Bank Of America And More

Financial news for PTLA dated on 2017-08-24: Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

Financial news for PTLA dated on 2017-08-24: The Market In 5 Minutes

Financial news for PTLA dated on 2017-08-24: Benzinga's Top Upgrades, Downgrades For August 24, 2017

Financial news for PTLA dated on 2017-08-24: Credit Suisse Upgrades Portola Pharmaceuticals to Outperform

Financial news for PTLA dated on 2017-08-15: Portola Pharma Reports AndexXa BLA Resubmission Accepted For Review By FDA

Financial news for PTLA dated on 2017-08-09: Portola Pharmaceuticals Reports Q2 EPS \$(1.22) vs \$(0.98) Est., Sales \$3.787M vs \$8.84M Est.

Financial news for PTLA dated on 2017-08-03: Portola Pharmaceuticals Reports Resubmission of Biologics License Application for AndexXa

Financial news for PTLA dated on 2017-07-05: Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days

Financial news for PTLA dated on 2017-06-26: A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside

Financial news for PTLA dated on 2017-06-26: Portola Pharmaceuticals: Expect Additional Upside From Here

Financial news for PTLA dated on 2017-06-23: Mid-Afternoon Market Update: Portola Climbs On FDA Approval For Bevyxxa; American Software Shares Plunge

Financial news for PTLA dated on 2017-06-23: Portola Pharma Shares Resume Trading, Now Up 45%

Financial news for PTLA dated on 2017-06-23: Portola Receives FDA Approval For Bevyxxa

Financial news for PTLA dated on 2017-06-23: Portola Pharma Shares To Resume Trading At 1:35pm ET

Financial news for PTLA dated on 2017-06-23: UPDATE: Portola PR Confirms FDA Approval Of Bevyxxa (betrixaban), Co. Expects To Launch Between August And November 2017

Financial news for PTLA dated on 2017-06-23: Portola Received FDA Approval For Bevyxxa In Acutely Ill Patients Not Undergoing Surgery

Financial news for PTLA dated on 2017-06-23: Traders Circulate FDA Document Appearing To Show FDA Approval For Portola Pharma's Betrixaban

Financial news for PTLA dated on 2017-06-23: Portola Pharma Shares Halted, News Pending; BZ Note: Co. Has FDA PDUFA Date Tomorrow

Financial news for PTLA dated on 2017-06-23: Citi Says Expect FDA PDUFA Decision For Portola Pharma Early

Financial news for PTLA dated on 2017-06-23: European Hematology Association (EHA) Congress 2017 Continues Today, Bellicum Pharma Expected To Present

Financial news for PTLA dated on 2017-06-22: European Hematology Association (EHA) Congress 2017 Begins Today, Day 1 of 4

Financial news for PTLA dated on 2017-06-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for PTLA dated on 2017-05-30: Tracking The Busy June PDUFA Calendar

Financial news for PTLA dated on 2017-05-08: Portola Pharma Reports Q1 EPS \$(0.74) vs \$(0.69) Est., Sales \$5.128M May Not Compare To \$20.46M Est.

Financial news for PTLA dated on 2017-04-10: Watch These 8 Huge Call Purchases In Monday Trade

Financial news for PTLA dated on 2017-04-07: Benzinga's Option Alert Recap From April 7

Financial news for PTLA dated on 2017-04-07: Option Alert: Portola Pharm May 40.0 Calls: 4770 @ ASK \$1.80: 5853 traded vs 15 OI: Earnings 5/4 After Close [est] \$35.95 Ref

Financial news for PTLA dated on 2017-02-28: Portola Pharmaceuticals Reports Q4 EPS \$(0.95) vs. \$(1.12) Est.

Financial news for PTLA dated on 2017-02-24: Oppenheimer Upgrades Portola Pharmaceuticals To Outperform

Financial news for PTLA dated on 2017-02-08: Portola Pharmaceuticals Reports FDA Has Told Co. It Hasn't Identified Issues At Mid-Cycle Review With Betrixaban That Require An Advisory Meeting

Financial news for PTLA dated on 2017-02-03: Portola Pharma Reports Signing of \$150M Royalty Deal with HealthCare Royalty Partners for Development, Commercialization of Andexanet Alfa

Financial news for PTLA dated on 2017-01-19: Oppenheimer Initiates Coverage On Portola Pharmaceuticals at Perform, Announces \$28.00 Target

Financial news for PTLA dated on 2017-01-13: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for PTLA dated on 2017-01-05: UPDATE: William Blair on Portola: Sees Two Drug Approvals in 2017, Says Andexxa, Betrixaban Worth At Least \$100/Share

Financial news for PTLA dated on 2017-01-05: Portola Pharma Shares Tick Higher as Hearing William Blair Making Positive Comments

Financial news for PTLA dated on 2016-12-30: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for PTLA dated on 2016-12-27: Physicians Likely To Support Portola's Betrixaban

Financial news for PTLA dated on 2016-12-27: Technical Alert: Portola Pharmaceuticals Surrenders Some Of Friday's Gains

Financial news for PTLA dated on 2016-12-27: Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead

Financial news for PTLA dated on 2016-12-27: 5 Biggest Price Target Changes For Tuesday

Financial news for PTLA dated on 2016-12-23: Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral

Financial news for PTLA dated on 2016-12-19: Portola Pharmaceuticals Enters into \$50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa

Financial news for PTLA dated on 2016-11-14: UPDATE: Portola Pharma Said APEX Substudy of Phase 3 Trial for Betrixaban Showed Significant Reduction in All-Cause Stroke, Ischemic Strong Through 77 Days of Follow Up

Financial news for PTLA dated on 2016-11-14: Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban

Financial news for PTLA dated on 2016-11-07: Portola Pharmaceuticals Q3 Loss/Share \$1.64 vs Est Loss/Share \$1.10, Revenue \$9.322M vs \$4.1M Est

Financial news for PTLA dated on 2016-11-07: Portola Pharma Reports Q3 EPS \$(1.64) vs \$(1.05) in Same Qtr. Last Year

Financial news for PTLA dated on 2016-11-01: 7 Stocks That Rallied Four Days, Then Sold Off Yesterday

Financial news for PTLA dated on 2016-10-28: 20 Stocks That Rallied Three Days On No News

Financial news for PTLA dated on 2016-10-25: Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients

Financial news for PTLA dated on 2016-10-20: 10 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for PTLA dated on 2016-09-22: Option Alert: PTLA Fri \$25 Calls at the bid: Volume of 1,722 @ 2.101 vs 451 Open Interest

Financial news for PTLA dated on 2016-08-30: Portola Pharmaceuticals Announces Encouraging Interim Results from Ongoing Phase 3b/4 ANNEXXA-4 Study of Factor Xa Inhibitor Antidote AndexXa in Patients with Acute Major Bleeding

Financial news for PTLA dated on 2016-08-19: Portola's AndexXa Still Approvable, But It Will Take Time

Financial news for PTLA dated on 2016-08-19: Citi Sees 'Too Much Risk' In Portola Pharma, Downgrades To Neutral

Financial news for PTLA dated on 2016-08-19: 7 Biggest Price Target Changes For Friday

Financial news for PTLA dated on 2016-08-19: Benzinga's Top Downgrades

Financial news for PTLA dated on 2016-08-19: Portola Pharma Reports Validation of MAA by EMA for IndexXa

Financial news for PTLA dated on 2016-08-19: Citigroup Downgrades Portola Pharmaceuticals to Neutral, Lowers PT to \$24.00

Financial news for PTLA dated on 2016-08-18: 12 Biggest Mid-Day Losers For Thursday

Financial news for PTLA dated on 2016-08-18: Mid-Day Market Update: Sunedison Semiconductor Surges Following GlobalWafers Buyout; Auris Medical Shares Drop

Financial news for PTLA dated on 2016-08-18: Mid-Morning Market Update: Markets Mostly Flat; Wal-Mart Tops Q2 Views

Financial news for PTLA dated on 2016-08-18: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTLA dated on 2016-08-18: PTLA Portola Pharmaceuticals Receives CRLfrom FDA for Biologics License Application for AndexXa

Financial news for PTLA dated on 2016-08-18: Watch These 7 Huge Put Purchases In Thursday Trade

Financial news for PTLA dated on 2016-08-17: Wednesday's Market Wrap: Major Averages Record Small Gains

Financial news for PTLA dated on 2016-08-17: Option Alert: PTLA Aug16 17.5 Puts: 500 @ ASK \$0.65: 809 traded vs 1935 OI: \$23.62 Ref

Financial news for PTLA dated on 2016-08-09: Portola Pharmaceuticals Reports Q2 EPS \$(1.02) vs. Est. \$(1.20)

Financial news for PTLA dated on 2016-06-01: Portola Phamra Reports Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer

Financial news for PTLA dated on 2016-05-31: Portola Pharma Risk-Reward Is Questionable

Financial news for PTLA dated on 2016-05-31: Credit Suisse Downgrades Portola Pharmaceuticals to Neutral, Lowers PT to \$30.00

Financial news for PTLA dated on 2016-05-27: Portola Pharmaceuticals Reveals Full Results Of Final Stage APEX Trial Of Betrixaban

Financial news for PTLA dated on 2016-05-27: Portola Pharma Reports Full Results of Phase 3 APEX Study of Betrixaban; Plans to Submit NDA, MAA in 2H'16

Financial news for PTLA dated on 2016-04-06: Portola Pharma Says Will Present Phase 3

APEX Study Results of Betrixaban at ISTH Meeting

Financial news for PTLA dated on 2016-04-04: Portola Pharmaceuticals, Daiichi Sankyo Partner To Develop Andexanet Alfa With Edoxaban In Japan

Financial news for PTLA dated on 2016-03-30: Deerfield Mgmt, L.P. Reports 5.48% Stake in Portola Pharmaceuticals in 13G

Financial news for PTLA dated on 2016-03-29: More Mid-Cap Biotech M&A May Be Coming

Financial news for PTLA dated on 2016-03-28: Stocks Hitting 52-Week Lows

Financial news for PTLA dated on 2016-03-28: Goldman Downgrades Portola Pharma To Neutral, Removes From Buy List

Financial news for PTLA dated on 2016-03-28: Goldman Sachs Downgrades Portola Pharmaceuticals to Neutral, Lowers PT to \$30.00, Removed From Conviction Buy List

Financial news for PTLA dated on 2016-03-24: Mid-Afternoon Market Update: PVH Rises On Upbeat Results; Portola Pharmaceuticals Shares Slide

Financial news for PTLA dated on 2016-03-24: Mid-Day Market Update: Crude Oil Down 2.8%; KB Home Shares Surge Following Strong Results

Financial news for PTLA dated on 2016-03-24: What Was So Bad About Results Of Portola's APEX Trial For Betrixaban?

Financial news for PTLA dated on 2016-03-24: The Market In 5 Minutes: Thursday, March 24, 2016

Financial news for PTLA dated on 2016-03-24: Stocks Hitting 52-Week Lows

Financial news for PTLA dated on 2016-03-24: Mid-Morning Market Update: Markets Open Lower; Finish Line Beats Q4 Expectations

Financial news for PTLA dated on 2016-03-24: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTLA dated on 2016-03-24: Portola Pharmaceuticals -30% Premarket @\$20.00 Following Resumption of Trade After Announcing Phase III Betrixaban Results

Financial news for PTLA dated on 2016-03-24: Shares of Portola Pharma Were Halted to Announce Results from APEX Trial of Betrixaban; Will Resume Trade at 7:30 a.m. EDT

Financial news for PTLA dated on 2016-03-24: Portola Pharma Offers Topline Results from Phase APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients

Financial news for PTLA dated on 2016-03-24: Portola Pharmaceuticals Announces Conference Call for Thursday, March 24, at 8:30 am ET to Provide Co Update

Financial news for PTLA dated on 2016-02-26: Portola Pharmaceuticals Reports Q4 Loss/Share \$(1.23) vs \$(1.12) Est; Revenue \$4.414M vs \$2.43M Est

Financial news for PTLA dated on 2016-02-17: Portola Pharmaceuticals Announces Biologics License Application for Andexanet Alfa Accepted for Review by FDA, Target FDA Action Date Aug. 17, 2016

Financial news for PTLA dated on 2016-02-01: UPDATE: Portola Pharma Licensing Deals for Andexanet Alfa in Japan Valued at Up to \$120M

Financial news for PTLA dated on 2016-02-01: Bristol-Myers and Pfizer Announce Collaboration with Portolooa Pharma

Financial news for PTLA dated on 2016-01-13: Portola Pharma. Shares Falling

Financial news for PTLA dated on 2015-12-18: Portola Pharmaceuticals Completes BLA Submission to U.S. Food and Drug Administration for Andexanet Alfa, Includes Data From Portola's Phase 3 ANNEXA Studies

Financial news for PTLA dated on 2015-12-05: Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at #ASH2015

Financial news for PTLA dated on 2015-12-04: Portola Reports Pricing Of Offering, 3.125M Shares At \$48/Share

Financial news for PTLA dated on 2015-12-03: Shares of Portola Pharma Down After Hours Following News of 2.6M Share Offering

Financial news for PTLA dated on 2015-11-11: The New England Journal of Medicine Publishes Results of Portola Pharmaceuticals' Phase 3 ANNEXA Studies of Andexanet Alfa

Financial news for PTLA dated on 2015-11-06: Portola Pharmaceuticals Reports Phase 3 ANNEXA-R Part 2 Study Results to be Presented at American Heart Association Scientific Sessions 2015

Financial news for PTLA dated on 2015-10-30: Portola Pharma Reports Closing of Enrollment in Pivotal Phase 3 APEX Study of Betrixaban for Blood Clots

Financial news for PTLA dated on 2015-10-13: Portola Pharmaceuticals Announces FDA Grants Fast Track Designation to Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients

Financial news for PTLA dated on 2015-09-24: Portola Pharmaceuticals Appoints Dr. David C. Stump to Board of Directors

Financial news for PTLA dated on 2015-09-15: Portola Pharmaceuticals Reports Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

Financial news for PTLA dated on 2015-06-24: Portola Pharmaceuticals Reports In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin Complex Concentrate Did Not

Financial news for PTLA dated on 2015-06-24: Why Does Credit Suisse Like Portola Pharma?

Financial news for PTLA dated on 2015-06-24: Credit Suisse Assumes Portola Pharmaceuticals at Outperform, Announces \$51.00 PT

Financial news for PTLA dated on 2015-06-23: Credit Suisse Initiates Coverage on Portola Pharmaceuticals at Outperform, Announces \$51.00 PT

Financial news for PTLA dated on 2015-06-22: Portola, Bristol-Myers Squibb, Pfizer Announce Complete Phase 3 ANNEXA-A Study Results

Financial news for PTLA dated on 2015-05-29: 2 Small Biotechs This Pro Is Watching

Financial news for PTLA dated on 2015-05-29: Portola Pharmaceuticals Showcases Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib

Financial news for PTLA dated on 2015-05-18: Portola Pharma Reports Will Present Data on Dual Kinase Inhibitor Cerdulatinib at ASCO

Financial news for PTLA dated on 2015-05-05: Portola Pharmaceuticals Announces Collaboration With Ora on PRT2761 in Ophthalmic Diseases

Financial news for PTLA dated on 2015-05-05: Portola Pharma Reports Collaboration with Ora for PRT2761 in Ophthalmic Diseases

Financial news for PTLA dated on 2015-04-08: Portola Pharmaceuticals Reports Brand New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint for Prolonged Reversal of Factor Xa Inhibitor Eliquis (apixaban)

Financial news for PTLA dated on 2015-03-09: Portola Pharmaceuticals Announces Proposed Offering of Common Stock

Financial news for PTLA dated on 2015-03-09: Portola Pharma Announces Offering of \$100M Stock

Financial news for PTLA dated on 2015-03-02: Portola Reports Q4 EPS -\$0.82 Vs Est -\$0.90, Announce Positive Phase 3 ANNEXA-R Study

Financial news for PTLA dated on 2015-02-26: Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa

Financial news for PTLA dated on 2015-01-12: Portola Pharmaceuticals Initiates Single-arm Phase 4 Study

Financial news for PTLA dated on 2015-01-09: What Investors Should Expect From Portola Pharmaceutical's Upcoming Data Readouts

Financial news for PTLA dated on 2015-01-09: Friday's Morning Movers: Earnings Start To Trickle In

Financial news for PTLA dated on 2015-01-09: Portola Pharma Announces Phase 3 Trial Met Primary Endpoints

Financial news for PTLA dated on 2014-11-17: UPDATE: Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)

Financial news for PTLA dated on 2014-11-17: Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)

Financial news for PTLA dated on 2014-11-17: Portola , Bristol-Myers Squibb, Pfizer Report Statistically Significant Results from First Part of Phase 3 ANNEXA-A Studies of Andexanet Alfa with Eliquis

Financial news for PTLA dated on 2014-11-10: Portola Pharma Reports Q3 EPS of \$(0.86) vs \$(0.92) Est; Revenue of \$2.43M vs \$2.73M Est

Financial news for PTLA dated on 2014-10-16: Portola Pharmaceuticals Announces Commercial Supply Agreement For Andexanet Alfa With Lonza

Financial news for PTLA dated on 2014-10-02: Portola Prices 6.25M Share Offering @\$26.00/Share

Financial news for PTLA dated on 2014-10-01: Portola Pharmaceuticals Announces Proposed Offering of Common Stock For Gross Proceeds Of \$160M

Financial news for PTLA dated on 2014-10-01: S-3 from Portola Pharma Shows Registration for 10M Share Common Stock Shelf Offering

Financial news for PTLA dated on 2014-10-01: Midday Gainers From October 1 - Angie's List Inc, Tekmira Pharmaceuticals Corporation And More

Financial news for PTLA dated on 2014-10-01: Morning Market Movers

Financial news for PTLA dated on 2014-10-01: Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Financial news for PTLA dated on 2014-07-07: UPDATE: Portola Will Receive Upfront Payment and Be Eligible for Milestone Payments

Financial news for PTLA dated on 2014-07-07: Portola Pharma Announces Entered Into Clinical Collab. Deal with Daiichi Sankyo for Phase 3 Studies of Andexanet Alfa and Edoxaban

Financial news for PTLA dated on 2014-07-02: 8-K from Portola Pharma Shows Co. Entered Commercial Supply Deal with CMC ICOS Biologics on Jul. 1st, Co. Will Make Immediate Upfront Payment of \$10M, to Make Reservation Payment of \$4.6M in Nov.

Financial news for PTLA dated on 2014-06-25: Top 4 Stocks In The Biotechnology Industry With The Highest EPS

Financial news for PTLA dated on 2014-06-11: Portola Pharma Announces Positive Results From Phase II Therapy With Andexanet Alfa and Enoxaparin

Financial news for PTLA dated on 2014-05-14: Portola To Announce Syk-JAK Results at American Society of Clinical Oncology May 30-June 3

Financial news for PTLA dated on 2014-03-27: Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban

Financial news for PTLA dated on 2014-03-19: Portola Pharma Begins Phase 3 Study of Andexanet Alfa, Sees Initial Data from Study in Q4'14, Sees Data from Second Part in Early '15

Financial news for PTLA dated on 2014-03-04: Morgan Stanley Maintains Overweight on Portola Pharma, Raises PT to \$40.00

Financial news for PTLA dated on 2014-02-03: Portola Pharma Announces Deal with Bayer, Janssen for Phase 3 Studies of Andexanet Alfa, XARELTO(R)

Financial news for PTLA dated on 2014-02-03: Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)

Financial news for PTLA dated on 2014-01-13: Portola Pharma Announces Second Clinical

Pact with Bristol-Myers, Will Study Andexanet Alfa with Eliquis, Will Receive Upfront, Milestone Payments

Financial news for PTLA dated on 2013-12-09: Portola Pharma Reports New Phase 2 Results Confirming Immediate, Dose-Dependent, Well-Tolerated Reversal of Anticoagulation Activity of XARELTO

Financial news for PTLA dated on 2013-11-25: Portola Pharma Reports FDA Breakthrough Therapy Designation for Andexanet Alfa (PRT4445)

Financial news for PTLA dated on 2013-11-11: Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*)

Financial news for PTLA dated on 2013-11-05: Portola Pharma Reports Q3 EPS of \$(0.53) vs \$(0.68) Est

Financial news for PTLA dated on 2013-10-17: Portola Pharma Prices 6.4M Shares at \$23.75/Share

Financial news for PTLA dated on 2013-10-16: SEC Filing from Portola Pharma Shows Prospectus for 4.46M Shares by Co., 1.91M Shares by Selling Holders

Financial news for PTLA dated on 2013-10-16: Amended S-1 Filing from Portola Pharma Shows Co. to Offer 4.8M Shares for Selling Holders

Financial news for PTLA dated on 2013-10-14: Portola Pharma Issues Results for First Phase 2 Trial Showing Extended Duration Infusion with PRT4445

Financial news for PTLA dated on 2013-10-03: Stocks Hitting 52-Week Highs

Financial news for PTLA dated on 2013-08-29: Portola Pharmaceuticals to Present Preclinical Data on Andexanet Alfa

Financial news for PTLA dated on 2013-08-15: Portola Pharma Reports Q2 EPS of \$(1.47) vs \$(0.71) Est

Financial news for PTLA dated on 2013-07-02: Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R)

Financial news for PTLA dated on 2013-06-26: Portola to Initiate Phase 2 Study Evaluating the Safety and Effectiveness of Its Factor Xa Inhibitor Antidote PRT4445 in Reversing the Anticoagulant Activity of Investigational Factor Xa Inhibitor Edoxaban

Financial news for PTLA dated on 2013-06-26: Portola Announces Oral Presentation of Phase 2 Data on PRT4445, Factor Xa Inhibitor Antidote, at 2013 International Society on Thrombosis and Haemostasis Congress

Financial news for PTLA dated on 2013-06-17: UPDATE: Credit Suisse Initiates Portola Pharmaceuticals at Outperform Rating Ahead of PIII APEX Trial

Financial news for PTLA dated on 2013-06-17: Credit Suisse Initiates Coverage on Portola Pharma at Outperform, Announces \$30.00 PT

Financial news for PTLA dated on 2013-06-17: UPDATE: Morgan Stanley Initiates Portola Pharmaceuticals at Overweight on Drugs Potentially Fulfilling Serious Medical Need

Financial news for PTLA dated on 2013-06-17: Benzinga's Top Initiations

Financial news for PTLA dated on 2013-06-17: Morgan Stanley Initiates Coverage on Portola Pharma at Overweight, Announces \$32.00 PT

Financial news for PTLA dated on 2013-05-29: Mid-Morning Market Update: Markets Tumble, Shuanghui To Acquire Smithfield Foods

Financial news for PTLA dated on 2013-05-28: Trading Released/Resumed: (NASDAQ: PTLA) Reason Not Available

Financial news for PTLA dated on 2013-05-22: Portola Pharma Opens for Trade at \$15.25/Share After Pricing at \$14.50

Financial news for PTLA dated on 2013-05-22: Portola Pharma IPO to Open for Quote at 10:45AM EDT, to Open at 11AM; Priced 8.42M Shares at \$14.50/Share, Initial Offering Was for 6.9M Shares in \$13-16/Share Range